FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has concluded not to enroll the remaining 3 patients in the Company’s ongoing Phase 2 clinical trial of onapristone in combination with Zytiga® (abiraterone acetate) in men with advanced castration-resistant prostate cancer (CRPC) who have failed Zytiga alone. This Phase 2 study protocol requires an efficacy review after the enrollment of 18 patients. To date, 15 patients have been enrolled. The Company does not believe the data collected from the first 12 patients in this study justifies the enrollment of additional subjects. The Company’s decision was not based on any safety signal and it will continue to monitor and to provide Onapristone to all patients currently enrolled in this trial.
The Company also announced that its Board of Directors is evaluating all potential development, strategic and other corporate opportunities available to the Company involving its onapristone, AR-42 and AR-12 product candidates.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development. For more information about the company, please visit www.arnothera.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, statements regarding the Company’s ability to consummate any corporate or other transaction involving its product candidates, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. Arno may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the Company has insufficient capital to fund its ongoing operations and may be unlikely to obtain additional capital in a timely manner, if ever, or on acceptable terms; that if the Company is unable to obtain additional capital or consummate a corporate or strategic transaction, it may be required to cease all operations; that the results of clinical trials will not support the Company’s claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates; regulatory risks; and the Company’s reliance on third party researchers and other collaborators. Additional risks are described in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.